NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

ABUS

Arbutus Biopharma Corp

May 09 • 11:51AM ET

3.30

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD REGN ALNY MRNA VRTX EXEL NBIX BMRN SRPT BLUE

| Held by: VTI IWM VXF IWO XBI IBB VTWO SCHA VHT IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.38	Insider Own	22.38%	Shs Outstand	189.96M	Perf Week	-8.08%
Market Cap	631.88M	Forward P/E	-	EPS next Y	-0.10	Insider Trans	-0.18%	Shs Float	148.63M	Perf Month	4.10%
Income	-69.92M	PEG	-	EPS next Q	-0.10	Inst Own	54.40%	Short Float	7.44%	Perf Quarter	-3.79%
Sales	6.17M	P/S	102.41	EPS this Y	43.68%	Inst Trans	2.68%	Short Ratio	10.62	Perf Half Y	-16.67%
Book/sh	0.51	P/B	6.44	EPS next Y	53.27%	ROA	-50.65%	Short Interest	11.05M	Perf Year	16.20%
Cash/sh	0.64	P/C	5.15	EPS next 5Y	49.14%	ROE	-68.76%	52W Range	2.70 - 4.72	Perf YTD	0.92%
Dividend Est.	-	P/FCF	-	EPS past 5Y	33.46%	ROI	-67.88%	52W High	-30.16%	Beta	1.28
Dividend TTM	-	Quick Ratio	8.15	Sales past 5Y	41.91%	Gross Margin	77.64%	52W Low	22.00%	ATR (14)	0.18
Dividend Ex-Date	-	Current Ratio	8.15	EPS Y/Y TTM	14.00%	Oper. Margin	-1133.92%	RSI (14)	48.30	Volatility	6.39% 5.75%
Employees	44	Debt/Eq	0.06	Sales Y/Y TTM	-65.98%	Profit Margin	-1133.04%	Recom	1.50	Target Price	5.25
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	42.46%	Payout	-	Rel Volume	0.38	Prev Close	3.30
Sales Surprise	0.69%	EPS Surprise	12.50%	Sales Q/Q	-26.62%	Earnings	Mar 27 BMO	Avg Volume	1.04M	Price	3.30
SMA20	-0.42%	SMA50	-0.19%	SMA200	-7.95%	Trades		Volume	157,122	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-02-22	Upgrade	Jefferies	Hold → Buy	$5
Feb-25-21	Initiated	Jefferies	Hold	$5
Dec-17-20	Initiated	H.C. Wainwright	Buy	$10
Jul-27-20	Resumed	JMP Securities	Mkt Outperform	$10 → $8
Jul-24-20	Downgrade	Robert W. Baird	Outperform → Neutral
May-19-20	Upgrade	Wedbush	Neutral → Outperform
Mar-06-20	Upgrade	Chardan Capital Markets	Neutral → Buy	$5
Feb-20-20	Initiated	Robert W. Baird	Outperform	$8
Feb-05-20	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$10
Oct-07-19	Reiterated	B. Riley FBR	Buy	$7 → $3
Oct-04-19	Downgrade	Chardan Capital Markets	Buy → Neutral
Oct-16-18	Upgrade	B. Riley FBR	Neutral → Buy	$11.50 → $9
Oct-15-18	Upgrade	Wedbush	Underperform → Neutral	$5
Oct-12-18	Reiterated	Chardan Capital Markets	Buy	$12 → $6.50
Jul-06-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral	$9 → $9
Mar-19-18	Resumed	Chardan Capital Markets	Buy	$8.25
Mar-19-18	Downgrade	Wedbush	Outperform → Neutral	$9 → $6
Jan-05-18	Initiated	B. Riley FBR, Inc.	Buy	$10
Apr-04-17	Upgrade	Chardan Capital Markets	Neutral → Buy	$3 → $6
Feb-01-17	Reiterated	Wedbush	Outperform	$13 → $10

Show Previous Ratings

May-07-25 02:01AM	Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 (GlobeNewswire)
Apr-25-25 09:40AM	Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Apr-24-25 10:02AM	Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-23-25 02:01AM	Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 (GlobeNewswire)
Mar-31-25 12:00PM	All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy (Zacks)
09:40AM	Loading…
09:40AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? (Zacks)
Mar-28-25 09:48AM	Arbutus Biopharma: A Wing And A Prayer (Seeking Alpha) +7.03%
09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
07:01AM	Novo gains Lexicon obesity drug; CRISPR COO to step down (BioPharma Dive)
Mar-27-25 08:45AM	Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-26-25 03:45PM	As Vaccine Skepticism Mounts, Modernas Business Grows More Precarious (Barrons.com)
Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire)
Feb-25-25 07:00AM	Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO (GlobeNewswire)
Feb-12-25 09:24AM	Is Arbutus Biopharma Corp. (ABUS) the Best Nasdaq Stock Under $5 to Buy? (Insider Monkey)
11:22AM	Loading…
Jan-16-25 11:22AM	Jim Cramer on Arbutus Biopharma Corporation (ABUS): It Loses Money (Insider Monkey)
Jan-13-25 07:30AM	Arbutus Provides 2025 Corporate and Financial Update (GlobeNewswire)
Dec-06-24 08:20AM	Heres Why Arbutus (ABUS) Surged in Q3 (Insider Monkey)
Dec-03-24 08:00AM	Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors (Business Wire)
Nov-26-24 07:30AM	Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat (GlobeNewswire)
Nov-15-24 11:02AM	Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon (GlobeNewswire)
11:01AM	Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B (GlobeNewswire)
Nov-14-24 07:30AM	Arbutus to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Nov-07-24 02:12AM	Arbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com)
02:07AM	Q3 2024 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-06-24 08:45AM	Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:40AM	Arbutus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-23-24 07:30AM	Arbutus to Report Third Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Oct-15-24 08:16AM	Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting 2024 (GlobeNewswire) +6.48%
07:30AM	Loading…
Oct-01-24 07:30AM	Arbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference (GlobeNewswire)
Sep-25-24 09:40AM	Has Arbutus Biopharma (ABUS) Outpaced Other Medical Stocks This Year? (Zacks)
Sep-03-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-22-24 09:40AM	Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-06-24 09:40AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-02-24 01:51AM	Q2 2024 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-01-24 08:40AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:41AM	Arbutus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-18-24 07:30AM	Arbutus to Report Second Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Jun-06-24 11:15AM	Treatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels (GlobeNewswire) -7.99%
11:15AM	Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B (GlobeNewswire)
Jun-05-24 02:30AM	Arbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure (GlobeNewswire) +8.68%
May-29-24 07:30AM	Arbutus to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 02:00AM	Arbutus to Present Imdusiran Data at EASL Congress 2024 (GlobeNewswire) +6.23%
May-17-24 12:03PM	Update: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program (MT Newswires)
10:40AM	Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program (MT Newswires)
09:00AM	Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value (Business Wire)
May-07-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-03-24 11:19AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:24AM	Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-02-24 12:55PM	ABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:58AM	Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review (GuruFocus.com)
08:45AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:44AM	Arbutus: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:25AM	Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024 (GlobeNewswire)
Apr-30-24 09:40AM	Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year? (Zacks)
Apr-18-24 07:30AM	Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Apr-04-24 08:30AM	Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna (GlobeNewswire)
Mar-08-24 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Mar-01-24 08:17AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 11:14PM	Q4 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
08:40AM	Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:52AM	Arbutus Biopharma Corp (ABUS) Reports Year-End Financial Results and Progress in Clinical Trials (GuruFocus.com)
07:30AM	Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-15-24 07:30AM	Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Jan-08-24 07:30AM	Arbutus Announces 2024 Corporate Objectives and Provides Financial Update (GlobeNewswire)
Nov-09-23 04:24PM	Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD (GlobeNewswire)
04:01PM	Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting (GlobeNewswire)
09:12AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 07:30AM	Arbutus to Present at Jefferies London Healthcare Conference (GlobeNewswire)
01:16AM	Q3 2023 Arbutus Biopharma Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:05AM	Arbutus Biopharma Corp (ABUS) Reports Q3 2023 Financial Results (GuruFocus.com)
07:40AM	Arbutus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:15AM	Arbutus Announces CEO, William Collier, to Retire December 31, 2023 (GlobeNewswire)
Oct-30-23 09:32AM	12 Best Micro Cap Stocks To Invest In (Insider Monkey)
Oct-24-23 07:30AM	Arbutus to Report Third Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Oct-18-23 07:30AM	Arbutus to Present at H.C. Wainwright 4th Annual Hepatitis B Virus (HBV) Virtual Conference (GlobeNewswire) -5.82%
Oct-11-23 08:05AM	Arbutus Announces Multiple Abstracts Accepted for Presentation at AASLD - The Liver Meeting 2023 (GlobeNewswire)
Sep-12-23 10:56AM	Arbutus BioPharma narrows research focus to extend cash runway (American City Business Journals) -7.73%
08:58AM	Arbutus (ABUS) to Focus on Hepatitis B Candidates, Stock Up (Zacks)
Sep-11-23 04:15PM	Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended (GlobeNewswire)
Sep-07-23 07:30AM	Arbutus to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Aug-04-23 03:29PM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-03-23 08:55AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:49AM	Arbutus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Jul-23-23 10:19AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) has caught the attention of institutional investors who hold a sizeable 38% stake (Simply Wall St.)
Jul-20-23 07:30AM	Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Jul-12-23 07:30AM	Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors (GlobeNewswire)
Jul-10-23 04:01PM	Arbutus Appoints Two New Executives (GlobeNewswire)
Jun-23-23 09:40AM	Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year? (Zacks)
Jun-21-23 07:30AM	Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody (GlobeNewswire)
02:01AM	Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023 (GlobeNewswire)
Jun-07-23 09:40AM	Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year? (Zacks)
02:01AM	Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023 (GlobeNewswire)
Jun-01-23 11:29AM	Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates (Zacks)
May-31-23 07:30AM	Arbutus to Present at Jefferies Healthcare Conference (GlobeNewswire)

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McElhaugh Michael J.	Director	Apr 21 '25	Proposed Sale	3.26	246,886	804,850		Apr 21 02:11 PM
McElhaugh Michael J.	Director	Apr 15 '25	Proposed Sale	3.20	53,114	170,098		Apr 15 04:27 PM
Sofia Michael J.	Officer	Mar 31 '25	Proposed Sale	3.50	250,000	875,000		Mar 31 09:42 AM
Sofia Michael J.	Officer	Mar 24 '25	Proposed Sale	3.28	250,000	820,000		Mar 24 09:19 AM
Sofia Michael J.	Officer	Mar 19 '25	Proposed Sale	3.20	150,000	480,000		Mar 19 09:34 AM
Sofia Michael J.	Officer	Mar 13 '25	Proposed Sale	3.38	100,000	338,000		Mar 13 03:55 PM
Sofia Michael J.	Member of immediate family of	Mar 07 '25	Proposed Sale	3.29	167,162	549,963		Mar 07 02:59 PM
HASTINGS DAVID C	Chief Financial Officer	Feb 04 '25	Sale	3.28	22,183	72,827	159,724	Feb 05 04:02 PM
Sims Karen	Chief Medical Officer	Feb 04 '25	Sale	3.28	19,348	63,519	106,194	Feb 05 04:02 PM
McElhaugh Michael J.	Interim President & CEO	Feb 04 '25	Sale	3.28	23,790	78,103	1,481,003	Feb 05 04:02 PM
Naftzger J. Christopher	General Counsel and CCO	Feb 04 '25	Sale	3.28	11,333	37,206	86,244	Feb 05 04:02 PM
David C. Hastings	Officer	Feb 04 '25	Proposed Sale	3.28	22,183	72,827		Feb 04 08:39 PM
Karen Sims	Officer	Feb 04 '25	Proposed Sale	3.28	19,348	63,519		Feb 04 08:38 PM
Michael J. McElhaugh	Director and Officer	Feb 04 '25	Proposed Sale	3.28	23,790	78,103		Feb 04 08:36 PM
J. Christopher Naftzger	Officer	Feb 04 '25	Proposed Sale	3.28	11,333	37,206		Feb 04 08:34 PM
MANCHESTER KEITH S	Director	Aug 14 '24	Option Exercise	0.56	54,915	30,752	54,915	Aug 16 04:07 PM
MANCHESTER KEITH S	Director	Aug 14 '24	Sale	3.69	8,846	32,637	46,069	Aug 16 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABUS

Arbutus Biopharma Corp

Upgrade your FINVIZ experience